FINWIRES · TerminalLIVE
FINWIRES

4DMedical Launches CLEAR Clinical Program to Target $3 Billion Pulmonary Embolism Market

By

4DMedical (ASX:4DX) launched CLEAR, a clinical evidence program designed to accelerate entry of its CT:VQ imaging technology into the acute pulmonary embolism market, targeting a $3 billion obtainable market in the US, according to a Tuesday Australian bourse filing.

The company said the core CLEAR study, which stands for Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism, is a multi-center, multinational, prospective, observational study putting CT:VQ head-to-head with computed tomography pulmonary angiography in patients with suspected pulmonary embolism, the filing added.

4DMedical has entered into a clinical research agreement with Mass General Brigham-affiliated teaching hospitals as the lead site for CLEAR, it added.

Related Articles

Asia

Market Chatter: Kioxia Seeks to Regain NAND Edge Against Rivals Like Samsung

Kioxia (TYO:285A) is seeking to recover lost market share by commercializing a new technology ahead of its competitors such as Samsung Electronics (KRX:005930), Nikkei Asia reported Tuesday, citing the company's engineer.The plan comes as rising demand for data center memory extends to NAND flash chips, the report said.The company is set to hold its first investor strategy briefing in a year on Tuesday, where Kioxia is expected to outline its technology roadmap, according to Nikkei.While Kioxia's predecessor Toshiba, pioneered vertical stacking technology for NAND in 2007, the company has recently lagged behind rivals in layer counts-its main products still use 218 layers, compared to SK Hynix's (KRX:000660) 300-plus-layer chip unveiled in summer 2023, the publication said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$KRX:000660$KRX:005930$TYO:285A
Asia

KITZ Closes 9.2 Billion Yen Acquisition of V TEX

KITZ (TYO:6498) has finalized the acquisition of all shares of V TEX, turning the industrial special valve and rupture disk manufacturer into a fully owned subsidiary, according to a Tokyo bourse filing on Monday.The transaction involved purchasing 886,400 shares for nearly 9.2 billion yen, with total costs including advisory fees reaching around 9.37 billion yen.Following the acquisition, an extraordinary general meeting of V TEX shareholders approved the appointment of new directors and corporate auditors, leading to a restructured management team that includes Kenji Kato as President & CEO.Several new appointees, such as part-time director Tomoya Maekawa and part-time corporate auditors Toshiyuki Murasawa and Kenichi Bessho, will concurrently hold positions at KITZ.V TEX will be consolidated into KITZ's financial statements starting from the second quarter of the fiscal year ending December, with any material impact on results to be disclosed later.

$TYO:6498
Asia

Atlas Arteria Continues to Reject IFM Global's Takeover Proposal

Atlas Arteria (ASX:ALX) issued a supplementary target statement that continues to recommend the rejection of a takeover bid by IFM Global Infrastructure Fund, according to a Tuesday filing with the Australian bourse.Atlas Arteria said it still believes the unsolicited IFM offer is too low, opportunistic, and highly conditional.An earlier bidder's statement filed by IFM "attempted to attack" some aspects of an independent expert analysis that Atlas is relying on, but the experts' panel remains satisfied that its opinions on the proposed deal "continue to be appropriate," Atlas said.Even if the offer's price was increased to the proposed maximum consideration, it would still materially undervalue Atlas, the company said, adding that the bidder is in a position to be able to pay more.

$ASX:ALX